Literature DB >> 12767822

Expression, purification, and isotope labeling of the Fv of the human HIV-1 neutralizing antibody 447-52D for NMR studies.

Naama Kessler1, Anat Zvi, Min Ji, Michal Sharon, Osnat Rosen, Rina Levy, Miroslaw Gorny, Suzan Zolla-Pazner, Jacob Anglister.   

Abstract

The Fv is the smallest antigen binding fragment of the antibody and is made of the variable domains of the light and heavy chains, V(L) and V(H), respectively. The 26-kDa Fv is amenable for structure determination in solution using multi-dimensional hetero-nuclear NMR spectroscopy. The human monoclonal antibody 447-52D neutralizes a broad spectrum of HIV-1 isolates. This anti-HIV-1 antibody elicited in an infected patient is directed against the third variable loop (V3) of the envelope glycoprotein (gp120) of the virus. The V3 loop is an immunodominant neutralizing epitope of HIV-1. To obtain the 447-52D Fv for NMR studies, an Escherichia coli bicistronic expression vector for the heterodimeric 447-52D Fv and vectors for single chain Fv and individually expressed V(H) and V(L) were constructed. A pelB signal peptide was linked to the antibody genes to enable secretion of the expressed polypeptides into the periplasm. For easy cloning of any antibody gene without potential modification of the antibody sequence, restriction sites were introduced in the pelB sequence and following the termination codon. A set of oligonucleotides that prime the leader peptide genes of all potential antibody human antibodies were designed as backward primers. The forward primers for the V(L) and V(H) were based on constant region sequences. The 447-52D Fv could not be expressed either by a bicistronic vector or as single chain Fv, probably due to its toxicity to Escherichia coli. High level of expression was obtained by individual expression of the V(H) and the V(L) chains, which were then purified and recombined to generate a soluble and active 447-52D Fv fragment. The V(L) of mAb 447-52D was uniformly labeled with 13C and 15N nuclei (U-13C/15N). Preliminary NMR spectra demonstrate that structure determination of the recombinant 447-52D Fv and its complex with V3 peptides is feasible.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12767822     DOI: 10.1016/s1046-5928(03)00047-0

Source DB:  PubMed          Journal:  Protein Expr Purif        ISSN: 1046-5928            Impact factor:   1.650


  4 in total

1.  Molecular switch for alternative conformations of the HIV-1 V3 region: implications for phenotype conversion.

Authors:  Osnat Rosen; Michal Sharon; Sabine R Quadt-Akabayov; Jacob Anglister
Journal:  Proc Natl Acad Sci U S A       Date:  2006-09-11       Impact factor: 11.205

2.  Structural basis of clade-specific HIV-1 neutralization by humanized anti-V3 monoclonal antibody KD-247.

Authors:  Karen A Kirby; Yee Tsuey Ong; Atsuko Hachiya; Thomas G Laughlin; Leslie A Chiang; Yun Pan; Jennifer L Moran; Bruno Marchand; Kamalendra Singh; Fabio Gallazzi; Thomas P Quinn; Kazuhisa Yoshimura; Toshio Murakami; Shuzo Matsushita; Stefan G Sarafianos
Journal:  FASEB J       Date:  2014-10-28       Impact factor: 5.191

3.  Diverse recombinant HIV-1 Envs fail to activate B cells expressing the germline B cell receptors of the broadly neutralizing anti-HIV-1 antibodies PG9 and 447-52D.

Authors:  Andrew T McGuire; Jolene A Glenn; Adriana Lippy; Leonidas Stamatatos
Journal:  J Virol       Date:  2013-12-18       Impact factor: 5.103

4.  Dynamics of antibody domains studied by solution NMR.

Authors:  Bang K Vu; Joseph D Walsh; Dimiter S Dimitrov; Rieko Ishima
Journal:  Methods Mol Biol       Date:  2009
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.